F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
Blood · 2023
DOI: 10.1182/blood.2022017871 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Guoqing Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hemophilia Comprehensive Care Center, Beijing Children's Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hemophilia B. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hemophilia Comprehensive Care Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Faculty of Laboratory Medicine, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
ORCID-Profile: Jie Sun, Zekun Li, Zhenping Chen, Runhui Wu
Zitieren
APA
Liu, G., Sun, J., Li, Z., Chen, Z., Wu, W., & Wu, R. (2023). F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B. Blood. https://doi.org/10.1182/blood.2022017871
Vancouver
Liu G, Sun J, Li Z, Chen Z, Wu W, Wu R. F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B. Blood. 2023. doi:10.1182/blood.2022017871
BibTeX
@article{Liu2023,
author = {Liu, Guoqing and Sun, Jie and Li, Zekun and Chen, Zhenping and Wu, Wenman and Wu, Runhui},
title = {F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022017871}
}
EUVIMED